Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A panel of experts was split Thursday on whether to recommend approval for ChemoCentryx's autoimmune disease drug — and CCXI stock plummeted to its lowest point in two years on Friday. The post ChemoCentryx Stock Loses Half Its Value; Is This The Final Nail For Its Drug?

ChemoCentryx Stock Loses Half Its Value; Is This The Final Nail For Its Drug?

The FDA's Arthritis Advisory Committee voted 10 for and 8 against the approval of ChemoCentryx Inc's (NASDAQ: CCXI) investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis. The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate to support approval.

Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate

SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (“Committee”) on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting, the Committee voted on three questions presented by the FDA:

ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your ChemoCentryx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal sec

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $CCXI #investors--The Law Offices of Frank R. Cruz Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $CCXI #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI) investors concerning the Company's possible violations of federal securities laws. ChemoCentryx is a biopharmaceutical company. Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (“AAV”). On July 9, 2020, ChemoCentryx announced that it had filed its New Drug Applicat

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors

New York, New York--(Newsfile Corp. - May 6, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) from November 26, 2019 through May 3, 2021 (the "Class Period"). The lawsuit filed in the...

DEADLINE FOR CCXI INVESTORS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ChemoCentryx, Inc.

NEW YORK, May 6, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) from November 26, 2019 through May 3, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

CCXI INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc.

RADNOR, Pa., May 6, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021 , inclusive (the "Class Period").

CCXI CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.

Los Angeles, California--(Newsfile Corp. - May 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The FDA released a "Briefing Document" on May 4, 2021, concerning ChemoCentryx's...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2021. SO WHAT: If you purchased ChemoCentryx securities during the Class Period yo

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – CCXI

MILWAUKEE, May 5, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against ChemoCentryx (NASDAQ: CCXI). The investigation results from inaccurate statements ChemoCentryx may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against ChemoCentryx Inc.

LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CCXI--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc. and Encourages Investors with Losses to Contact the Firm

SAN FRANCISCO, May 5, 2021 /PRNewswire/ -- Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ChemoCentryx (CCXI) Investors with Losses to Contact Its Attorneys Now, FDA Briefing Document Raises Serious Questions, Firm Investigating Possible Securities Law Violations

LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CCXI--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc. and Encourages Investors with Losses to Contact the Firm

The FDA's briefing documents for an advisory committee don't appear to bode well for avacopan's chances of approval.

Why ChemoCentryx Stock Crashed Today

Bioline RX

Cocrystal Pharma

Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.

Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today

Boston, Massachusetts--(Newsfile Corp. - May 4, 2021) - Block & Leviton LLP announces that the firm is investigating whether ChemoCentryx, Inc. (NASDAQ: CCXI) committed securities fraud. Investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, please visit https://www.blockleviton.com/cases/ccxi.What is this all about?On May 4, 2021, the U.S. Food and Drug Administration released a "Briefing Document" concerning ChemoCentryx's drug candidate avacopan, which is...

Investors Who Have Lost Money in Their ChemoCentryx, Inc. Investment Should Contact Block & Leviton, Who Is Investigating Potential Securities Fraud Claims Against ChemoCentryx

ChemoCentryx Inc (NASDAQ: CCXI) shares plunged after an FDA briefing document indicates the agency has “several areas of concerns” with its vasculitis candidate, avacopan. The FDA document raised questions regarding the “interpretability of the data and the clinical meaningfulness of these results” as summarized below: At Week 26, the proportion of patients in disease remission in the avacopan group (72.3%) was non-inferior to the prednisone group (70.1%) according to the Applicant's testing plan.

ChemoCentryx Stock Plunges As FDA Briefing Document Casts Doubt On Vasculitis Candidate Avacopan's Data

ChemoCentryx, Inc. (NASDAQ: CCXI) shares are trading lower after FDA briefing documents for avacopan identified areas of concern, which raised "uncertainties about the interpretability" of data and the "clinical meaningfulness" of results. FDA briefing doc for ChemoCentryx's Avacopan shows candidate "is an efficacious treatment for patients with this rare disease and fulfills unmet medical needs for this patient population.

Why ChemoCentryx's Stock Is Plunging Today

The stock price of ChemoCentryx Inc (NASDAQ: CCXI) fell from $48.82 to $24.60 (down 49.61%) during intraday trading. This is why it happened.

CCXI Stock: From $48.82 To $24.60 (49.61% Decrease) Intraday Explanation

Shares of ChemoCentryx Inc. plunged 44.8% in trading on Tuesday after the Food and Drug Administration questioned the rationale behind some of the clinical data for avacopan, an experimental treatment for a rare autoimmune disease. The document was released in advance of a FDA advisory committee scheduled for Thursday.

ChemoCentryx's stock dives after critique from the FDA about experimental treatment for rare autoimmune disease

ChemoCentryx, Inc.'s (CCXI) CEO Dr. Thomas Schall on Q1 2021 Results - Earnings Call Transcript

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -7.50% and 19.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Reports Q1 Loss, Tops Revenue Estimates

Shares of ChemoCentryx (NASDAQ:CCXI) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 22.86% over the past year to ($0.43), which missed the estimate of ($0.40).

News for Chemocentryx Stock (CCXI)